---
input_text: 'Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
  Importance: Small cell lung cancer (SCLC) is an aggressive disease that is characterized
  by rapid growth and the early development of metastases. Patients typically respond
  to initial chemotherapy but quickly experience relapse, resulting in a poor long-term
  outcome. Therapeutic innovations that substantially improve survival have historically
  been limited, and reliable, predictive biomarkers are lacking. Observations: This
  review examines the biologic characteristics of SCLC, the current treatment landscape,
  and ongoing efforts to identify novel therapeutic targets. Ongoing research has
  advanced the understanding of molecular categories and the immunologic microenvironment
  of SCLC, which in turn has helped improve disease classification and staging. Recently,
  immunotherapy-based regimens have become available for the management of SCLC, with
  2 programmed cell death 1 ligand 1 inhibitors approved in combination with chemotherapy
  for first-line treatment of extensive-stage disease. For second-line treatment,
  a novel alkylating agent, lurbinectedin, which inhibits oncogenic transcription,
  has been approved for use in patients with metastatic SCLC. Furthermore, a wide
  variety of therapies and innovative combination regimens are being continuously
  evaluated. Potential therapeutic strategies, including aurora kinase A inhibitors,
  polyadenosine diphosphate-ribose polymerase inhibitors, ataxia telangiectasia and
  Rad3-related inhibitors, cyclin-dependent kinase 7 inhibitors, delta-like protein
  3 agents, antiganglioside agents, CD47 inhibitors, and lysine-specific histone demethylase
  1a inhibitors, are also being examined. Conclusions and Relevance: Therapeutic optimization
  of SCLC remains a challenge, but recent trial results and drug approvals are encouraging.
  Advances in research have revealed critical information regarding biologic characteristics
  of the disease, which may lead to the identification of vulnerabilities and the
  development of new therapies. Further research focused on identifying biomarkers
  and evaluating innovative therapies will be paramount to improving treatment outcomes
  for patients with SCLC.'
raw_completion_output: |-
  primary_disease: Small Cell Lung Cancer (SCLC)

  medical_actions: chemotherapy; immunotherapy-based regimens; use of programmed cell death 1 ligand 1 inhibitors in combination with chemotherapy; use of lurbinectedin; evaluation of aurora kinase A inhibitors; evaluation of polyadenosine diphosphate-ribose polymerase inhibitors; evaluation of ataxia telangiectasia and Rad3-related inhibitors; evaluation of cyclin-dependent kinase 7 inhibitors; evaluation of delta-like protein 3 agents; evaluation of antiganglioside agents; evaluation of CD47 inhibitors; evaluation of lysine-specific histone demethylase 1a inhibitors

  symptoms: rapid growth; early development of metastases; relapse

  chemicals: programmed cell death 1 ligand 1 inhibitors; lurbinectedin; aurora kinase A inhibitors; polyadenosine diphosphate-ribose polymerase inhibitors; ataxia telangiectasia and Rad3-related inhibitors; cyclin-dependent kinase 7 inhibitors; delta-like protein 3 agents; antiganglioside agents; CD47 inhibitors; lysine-specific histone demethylase 1a inhibitors

  action_annotation_relationships: chemotherapy TREATS rapid growth IN Small Cell Lung Cancer (SCLC); chemotherapy TREATS early development of metastases IN Small Cell Lung Cancer (SCLC); chemotherapy TREATS relapse IN Small Cell Lung Cancer (SCLC); immunotherapy-based regimens (with programmed cell death 1 ligand 1 inhibitors) TREATS rapid growth IN Small Cell Lung Cancer (SCLC); immunotherapy-based regimens (with programmed cell death 1 ligand 1 inhibitors) TREATS early development of metastases IN Small Cell Lung Cancer (SCLC); use of lurbinectedin TREATS relapse IN Small Cell Lung Cancer (SCLC); evaluation of aurora kinase A inhibitors PREVENTS rapid growth IN Small Cell Lung Cancer (SCLC); evaluation of polyadenosine diphosphate-ribose polymerase inhibitors PREVENTS early development of metastases IN Small Cell Lung Cancer (SCLC); evaluation of ataxia telangiectasia and Rad3-related inhibitors PREVENTS relapse IN Small Cell Lung Cancer (SCLC); evaluation of cyclin-dependent kinase 7 inhibitors PREVENTS rapid growth IN Small Cell Lung Cancer (SCLC); evaluation of delta-like
prompt: |+
  Split the following piece of text into fields in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  evaluation of delta-like

  ===

extracted_object:
  primary_disease: MONDO:0008433
  medical_actions:
    - MAXO:0000647
    - immunotherapy-based regimens
    - use of programmed cell death 1 ligand 1 inhibitors in combination with chemotherapy
    - use of lurbinectedin
    - evaluation of aurora kinase A inhibitors
    - evaluation of polyadenosine diphosphate-ribose polymerase inhibitors
    - evaluation of ataxia telangiectasia and Rad3-related inhibitors
    - evaluation of cyclin-dependent kinase 7 inhibitors
    - evaluation of delta-like protein 3 agents
    - evaluation of antiganglioside agents
    - evaluation of CD47 inhibitors
    - evaluation of lysine-specific histone demethylase 1a inhibitors
  symptoms:
    - rapid growth
    - early development of metastases
    - relapse
  chemicals:
    - programmed cell death 1 ligand 1 inhibitors
    - lurbinectedin
    - aurora kinase A inhibitors
    - polyadenosine diphosphate-ribose polymerase inhibitors
    - ataxia telangiectasia and Rad3-related inhibitors
    - cyclin-dependent kinase 7 inhibitors
    - delta-like protein 3 agents
    - antiganglioside agents
    - CD47 inhibitors
    - CHEBI:131509
  action_annotation_relationships:
    - subject: <chemotherapy>
      predicate: <TREATS>
      object: <rapid growth>
      qualifier: MONDO:0008433
      subject_extension: <chemotherapy>
    - subject: MAXO:0000647
      predicate: TREATS
      object: early development of metastases
      qualifier: MONDO:0008433
      subject_extension: chemotherapy
    - subject: MAXO:0000647
      predicate: TREATS
      object: relapse
      qualifier: MONDO:0008433
    - subject: immunotherapy-based regimens
      predicate: TREATS
      object: rapid growth
      qualifier: MONDO:0008433
      subject_qualifier: with programmed cell death 1 ligand 1 inhibitors
      subject_extension: programmed cell death 1 ligand 1 inhibitors
    - subject: immunotherapy-based regimens
      predicate: TREATS
      object: development of metastases
      qualifier: MONDO:0008433
      subject_qualifier: with programmed cell death 1 ligand 1 inhibitors
      object_qualifier: early
      subject_extension: programmed cell death 1 ligand 1 inhibitors
      object_extension: early
    - subject: use of lurbinectedin
      predicate: TREATS
      object: relapse
      qualifier: MONDO:0008433
      subject_extension: lurbinectedin
    - subject: evaluation of aurora kinase A inhibitors
      predicate: PREVENTS
      object: rapid growth
      qualifier: MONDO:0008433
      subject_extension: aurora kinase A inhibitors
    - subject: evaluation of polyadenosine diphosphate-ribose polymerase inhibitors
      predicate: PREVENTS
      object: early development of metastases
      qualifier: MONDO:0008433
      subject_extension: polyadenosine diphosphate-ribose polymerase inhibitors
    - subject: evaluation
      predicate: PREVENTS
      object: relapse
      qualifier: MONDO:0008433
      subject_extension: ataxia telangiectasia and Rad3-related inhibitors
    - subject: <evaluation>
      predicate: <PREVENTS>
      object: <rapid growth>
      qualifier: MONDO:0008433
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <cyclin-dependent kinase 7 inhibitors>
      object_extension: <rapid growth>
named_entities:
  - id: MONDO:0005086
    label: Renal cell carcinoma
  - id: MONDO:0003060
    label: Biliary tract cancer (BTC)
  - id: CHEBI:175901
    label: Gemcitabine
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: MONDO:0008840
    label: Ataxia Telangiectasia
  - id: MAXO:0010030
    label: Bone Marrow Transplantation
  - id: MAXO:0001001
    label: Gene Therapy
  - id: CHEBI:166830
    label: Acetyl-DL-leucine
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:4462
    label: Dexamethasone sodium phosphate
  - id: CHEBI:133021
    label: venetoclax
  - id: HP:0002721
    label: Immunodeficiency
  - id: HP:0002073
    label: progressive cerebellar ataxia
  - id: HP:0002013
    label: vomiting
  - id: HP:0002315
    label: headache
  - id: CHEBI:27899
    label: cisplatin
  - id: HP:0001903
    label: Anemia
  - id: HP:0001873
    label: Thrombocytopenia
  - id: HP:0001875
    label: Neutropenia
  - id: CHEBI:231342
    label: Ceralasertib
  - id: CHEBI:31355
    label: Carboplatin
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: MONDO:0005184
    label: Pancreatic ductal adenocarcinoma (PDAC)
  - id: HP:0020174
    label: Drug resistance
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0010150
    label: Head and neck squamous cell carcinomas (HNSCC)
  - id: MAXO:0000014
    label: Radiotherapy (RT)
  - id: HP:0010280
    label: Oral mucositis
  - id: HP:0002015
    label: Dysphagia
  - id: MONDO:0008876
    label: Bloom Syndrome (BS)
  - id: HP:0001510
    label: growth retardation
  - id: HP:0011793
    label: malignancies
  - id: MONDO:0004992
    label: Cancer
  - id: HP:0002664
    label: Cancer
  - id: CHEBI:27656
    label: Camptothecin (CPT)
  - id: CHEBI:63632
    label: Topotecan
  - id: CHEBI:4911
    label: Etoposide
  - id: CHEBI:231344
    label: Talazoparib
  - id: CHEBI:231616
    label: M4344
  - id: MONDO:0008433
    label: Small-cell lung cancer (SCLC)
  - id: HP:0030357
    label: Small-cell lung cancer (SCLC)
  - id: MONDO:0003778
    label: Inborn Errors of Immunity (IEI)
  - id: HP:0033141
    label: Severe SARS-CoV-2 infection
  - id: MAXO:0001017
    label: Vaccination
  - id: CHEBI:22907
    label: Bleomycin (BLM)
  - id: MONDO:0005494
    label: Triple-negative breast cancer (TNBC)
  - id: CHEBI:9555
    label: 6-thioguanine
  - id: CHEBI:4659
    label: Disulfiram
  - id: CHEBI:28694
    label: Cu
  - id: CHEBI:83766
    label: Olaparib
  - id: HP:0002894
    label: pancreatic cancer
  - id: MONDO:0005192
    label: Pancreatic Cancer
  - id: MONDO:0007254
    label: Breast Cancer
  - id: MAXO:0000127
    label: Genetic testing
  - id: HP:0003002
    label: Breast Cancer
  - id: MONDO:0008903
    label: lung cancer
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0005070
    label: Tumors
  - id: MAXO:0001394
    label: Oral administration
  - id: MONDO:0036501
    label: Refractory Cancer
  - id: CHEBI:45863
    label: Paclitaxel
  - id: MONDO:0018177
    label: Glioblastoma
  - id: MAXO:0000004
    label: Surgery
  - id: HP:0012174
    label: Glioblastoma
  - id: MONDO:0009807
    label: Osteosarcoma
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:132992
    label: radiosensitizers
  - id: MONDO:0005575
    label: colorectal cancer
  - id: CHEBI:62913
    label: poly (ADP-ribose) polymerase (PARP) inhibitors
  - id: HP:0010310
    label: Chylothorax
  - id: CHEBI:3638
    label: Chloroquine
  - id: CHEBI:27563
    label: Arsenic
  - id: CHEBI:229924
    label: pifithrin-alpha (PFTalpha)
  - id: CHEBI:29678
    label: Sodium arsenite (NaAsO2)
  - id: CHEBI:41774
    label: Tamoxifen
  - id: MONDO:0004986
    label: Bladder cancer
  - id: HP:0009725
    label: Bladder cancer
  - id: MONDO:0968974
    label: Large B-Cell Lymphoma (LBCL)
  - id: MAXO:0000381
    label: Lymph node biopsy
  - id: CHEBI:64357
    label: Rituximab
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:8382
    label: Prednisone
  - id: MONDO:0005623
    label: AT (Autoimmune Thyroiditis)
  - id: MONDO:0008315
    label: Prostate Cancer
  - id: CHEBI:4672
    label: Docetaxel
  - id: HP:0012125
    label: Prostate Cancer
  - id: CHEBI:50914
    label: PI3K inhibitors
  - id: CHEBI:34936
    label: di-phenoxy acetamide (DPA) analogs
  - id: CHEBI:25555
    label: Compound DPA (7n)
  - id: HP:0000988
    label: rash
  - id: CHEBI:31348
    label: capecitabine
  - id: CHEBI:16044
    label: MET
  - id: HP:0100526
    label: Lung cancer
  - id: MONDO:0019600
    label: Xeroderma pigmentosum (XP)
  - id: CHEBI:131808
    label: Thymidine dimers
  - id: CHEBI:28300
    label: Glutamine
  - id: CHEBI:16856
    label: Glutathione
  - id: CHEBI:16810
    label: Alpha-ketoglutarate
  - id: HP:0000657
    label: Oculomotor apraxia
  - id: HP:0001266
    label: Choreoathetosis
  - id: CHEBI:4806
    label: Epigallocatechin-3-gallate (EGCG)
  - id: CHEBI:16240
    label: H2O2
  - id: CHEBI:229722
    label: RP-3500
  - id: CHEBI:135702
    label: Belotecan
  - id: CHEBI:229661
    label: Omaveloxolone
  - id: CHEBI:8863
    label: riluzole
  - id: MAXO:0000058
    label: pharmacotherapy
  - id: MONDO:0100339
    label: Friedreich ataxia
  - id: MONDO:0005140
    label: Epithelial ovarian cancer
  - id: HP:0002018
    label: Nausea
  - id: HP:0012378
    label: Fatigue
  - id: HP:0002039
    label: Anorexia
  - id: MONDO:0005233
    label: Non-small cell lung cancer
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: CHEBI:3077
    label: Betamethasone
  - id: CHEBI:30884
    label: Glucocorticoids (GCs)
  - id: MONDO:0024331
    label: Colorectal Cancer (CRC)
  - id: MONDO:0005061
    label: Lung adenocarcinoma (LUAD)
  - id: HP:0030078
    label: Lung adenocarcinoma
  - id: HP:0025318
    label: epithelial ovarian cancer
  - id: CHEBI:46345
    label: 5-fluorouracil
  - id: CHEBI:31941
    label: Oxaliplatin
  - id: CHEBI:80630
    label: Irinotecan
  - id: CHEBI:131509
    label: lysine-specific histone demethylase 1a inhibitors
